Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 849Triple Negative Breast Neoplasms 136Ovarian Neoplasms 55Colorectal Neoplasms 49Carcinoma, Non-Small-Cell Lung 47Neoplasms 43Neoplasm Metastasis 43Prostatic Neoplasms 42Lung Neoplasms 38Melanoma 30Carcinoma, Intraductal, Noninfiltrating 29Uterine Cervical Neoplasms 27Pancreatic Neoplasms 25Colonic Neoplasms 25Stomach Neoplasms 23Squamous Cell Carcinoma of Head and Neck 23Endometrial Neoplasms 23Carcinoma, Renal Cell 23Breast Carcinoma In Situ 22Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Motor Activity 16Inflammatory Breast Neoplasms 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 14Breast Cancer Female 13Brain Neoplasms 12Anatomic Stage I Breast Cancer AJCC v8 12Gastrointestinal Neoplasms 11

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-Positive Primary Breast Cancer × Breast × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡